Liver transplantation for hepatitis B

Hepatology Research

Volumn 29, Issue 4, 2004, Pages 193-201

  Bui Han, Steven Huy ^a   Martin, Paul ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Adefovir dipivoxil; HBIG; Lamivudine; Liver transplantation; Prophylaxis; Recurrent hepatitis B

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; DEATH; DRUG COST; DRUG EFFICACY; DRUG POTENCY; GRAFT REJECTION; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; SIDE EFFECT; VIRUS MUTANT;

EID: 4043172848     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2004.02.015     Document Type: Review

References (75)

1. Lok A.S. Prevention of recurrent hepatitis B post-liver transplantation Liver Transpl. 8 2002 S67-S73
2. Samuel D. Muller R. Alexander G. et al. Liver transplantation in European patients with the hepatitis B surface antigen [see comments] N Engl J Med. 329 1993 1842-1847
3. al-Hemsi B. McGory R.W. Shepard B. et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization Clin Transplant. 10 1996 668-675
4. McGory R.W. Ishitani M.B. Oliveira W.M. et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization Transplantation. 61 1996 1358-1364
5. Muller R. Gubernatis G. Farle M. et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization J Hepatol. 13 1991 90-96
6. Nymann T. Shokouh-Amiri M.H. Vera S.R. et al. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation Clin Transplant. 10 1996 663-667
7. Samuel D. Bismuth A. Mathieu D. et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients Lancet 337 1991 813-815
8. Sawyer R.G. McGory R.W. Gaffey M.J. et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization Ann Surg. 227 1998 841-850
9. Terrault N.A. Zhou S. Combs C. et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin Hepatology 24 1996 1327-1333
10. Terrault N.A. Zhou S. McCory R.W. Pruett T.L. Lake J.R. Roberts J.P. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin Hepatology. 28 1998 555-561
11. Ghany M.G. Ayola B. Villamil F.G. Gish R.G. Rojter S. Vierling J.M. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis [see comments] Hepatology 27 1998 213-222
12. Lo C.M. Cheung S.T. Lai C.L. et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis Ann Surg. 233 2001 276-281
13. Mutimer D. Dusheiko G. Barrett C. et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up Transplantation. 70 2000 809-815
14. Perrillo R.P. Wright T. Rakela J. Levy G. Schiff E. Gish R. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B Hepatology 33 2001 424-432
15. Grellier L. Mutimer D. Ahmed M. et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis Lancet 348 1996 1212-1215
16. Mutimer D. Pillay D. Dragon E. et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation J Hepatol. 30 1999 715-721
17. Allen M.I. Deslauriers M. Andrews C.W. et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group Hepatology. 27 1998 1670-1677
18. Bartholomew M.M. Jansen R.W. Jeffers L.J. Reddy K.R. Johnson L.C. Bunzendahl H. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [see comments] Lancet 349 1997 20-22
19. Ono-Nita S.K. Kato N. Shiratori Y. et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by In vitro full-length viral DNA transfection [In Process Citation] Hepatology 29 1999 939-945
20. Tipples G.A. Ma M.M. Fischer K.P. Bain V.G. Kneteman N.M. Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo Hepatology 24 1996 714-717
21. Villeneuve J.P. Condreay L.D. Willems B. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B Hepatology 31 2000 207-210
22. Yao F.Y. Terrault N.A. Freise C. Maslow L. Bass N.M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort Hepatology 34 2001 411-416
23. Fontana R.J. Keeffe E.B. Carey W. et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B Liver Transpl. 8 2002 433-439
24. Saab S. Kim M. Wright T.L. Han S.H. Martin P. Busuttil R.W. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus Gastroenterology 119 2000 1382-1384
25. Angus P.W. McCaughan G.W. Gane E.J. Crawford D.H. Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B Liver Transpl. 6 2000 429-433
26. Han S.H. Ofman J. Holt C. et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy Liver Transpl. 6 2000 741-748
27. Han S.H. Martin P. Edelstein M. et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation Liver Transpl. 9 2003 182-187
28. Markowitz J.S. Martin P. Conrad A.J. et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin Hepatology 28 1998 585-589
29. Marzan A. Salizzoni M. Debernardi-Venon W. et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis J Hepatol. 34 2001 903-910
30. Rosenau J. Bahr M.J. Tillmann H.L. et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection J Hepatol. 34 2001 895-902
31. Seehofer D. Rayes N. Naumann U. et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation Transplantation 72 2001 1381-1385
32. Yao F.Y. Osorio R.W. Roberts J.P. et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation Liver Transpl Surg. 5 1999 491-496
33. Yoshida E.M. Erb S.R. Partovi N. et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin Liver Transpl Surg. 5 1999 520-525
34. Naoumov N.V. Lopes A.R. Burra P. et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation J Hepatol. 34 2001 888-894
35. Dodson S.F. de Vera M.E. Bonham C.A. Geller D.A. Rakela J. Fung J.J. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation Liver Transpl. 6 2000 434-439
36. Sanchez-Fueyo A. Rimola A. Grande L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation Hepatology 31 2000 496-501
37. Angelico M. Di Paolo D. Trinito M.O. et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis Hepatology 35 2002 176-181
38. Barcena M.R. Cid G.L. Lopez S.P. Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine Transplant Proc. 35 2003 1841-1843
39. Perrillo R. Hann H.W. Mutimer D. et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 2004 81-90
40. Mutimer D. Feraz-Neto B.H. Harrison R. et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir Gut. 49 2001 860-863
41. Perrillo R. Schiff E. Yoshida E. et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants Hepatology 32 2000 129-134
42. Walsh K.M. Woodall T. Lamy P. Wight D.G. Bloor S. Alexander G.J. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus Gut. 49 2001 436-440
43. Perrillo R. Schiff E. Hann H.W. et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine-preliminary 24 week results. Hepatology 2001;34. Ref Type: Abstract.
44. Schiff E. Neuhaus P. Tillmann H.L. et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 2001;34. Ref Type: Abstract.
45. Peters M.G. Singer G. Howard T. et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin Transplantation 68 1999 1912-1914
46. Ling R. Mutimer D. Ahmed M. Boxall E.H. Elias E. Dusheiko G.M. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 24 1996 711-713
47. Fang J.W. Tung F.Y. Davis G.L. Dolson D.J. Van Thiel D.H. Lau J.Y. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant Gastroenterology 105 1993 901-904
48. Benner K.G. Lee R.G. Keeffe E.B. Lopez R.R. Sasaki A.W. Pinson C.W. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation Gastroenterology 103 1992 1307-1312
49. Angus P.W. Locarnini S.A. McCaughan G.W. Jones R.M. McMillan J.S. Bowden D.S. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation Hepatology 21 1995 14-18
50. Perrillo R. Rakela J. Dienstag J. et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group Hepatology 29 1999 1581-1586
51. Fischer L. Sterneck M. Zollner B. Rogiers X. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation Transplant Proc. 32 2000 2128-2130
52. Rayes N. Seehofer D. Hopf U. et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation Transplantation 71 2001 96-101
53. Malkan G. Cattral M.S. Humar A. et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience Transplantation 69 2000 1403-1407
54. Ben Ari Z. Mor E. Shapira Z. Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation Liver Transpl. 7 2001 113-117
55. Nery J.R. Weppler D. Rodriguez M. Ruiz P. Schiff E.R. Tzakis A.G. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation Transplantation. 65 1998 1615-1621
56. Honkoop P. De Man R.A. Niesters H.G. Zondervan P.E. Schalm S.W. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy Hepatology 32 2000 635-639
57. Seehofer D. Rayes N. Steinmuller T. et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation Liver Transpl. 7 2001 976-982
58. De Man R.A. Bartholomeusz A.I. Niesters H.G. Zondervan P.E. Locarnini S.A. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss J Hepatol. 29 1998 669-675
59. Marcellin P. Chang T.T. Lim S.G. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med. 348 2003 808-816
60. Hadziyannis S.J. Tassopoulos N.C. Heathcote E.J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med. 348 2003 800-807
61. Terrault N.A. Holland C.C. Ferrell L. et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation Liver Transpl Surg. 2 1996 132-138
62. Seehofer D. Rayes N. Neuhaus R. et al. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation. Transpl Int 2000;13(Suppl 1):S359-62.
63. Ben Ari Z. Shmueli D. Shapira Z. Mor E. Tur-Kaspa R. Loss of serum HBsAg after interferon-A therapy in liver transplant patients with recurrent hepatitis-B infection Liver Transpl Surg. 3 1997 394-397
64. Kruger M. Tillmann H.L. Trautwein C. et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study Liver Transpl Surg. 2 1996 253-262
65. Terrault N.A. Treatment of recurrent hepatitis B infection in liver transplant recipients Liver Transpl. 8 2002 S74-S81
66. Han S.H. Kinkhabwala M. Martin P. et al. Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir Am J Gastroenterol. 93 1998 2245-2247
67. Haller G.W. Bechstein W.O. Neuhaus R. et al. Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation Transpl Int. 9Suppl 1 1996 S210-S212
68. Manns M.P. Neuhaus P. Atkinson G.F. et al. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study Transpl Infect Dis. 3 2001 16-23
69. Berenguer M. Prieto M. Rayon M. et al. Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results Am J Gastroenterol. 96 2001 526-533
70. Rayes N. Seehofer D. Bechstein W.O. et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation Clin Transplant. 13 1999 447-452
71. Roche B. Samuel D. Gigou M. et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation J Hepatol. 31 1999 584-592
72. Jamal H. Regenstein F. Farr G. Perrillo R.P. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy Am J Gastroenterol. 91 1996 1027-1030
73. Gish R.G. Lau J.Y. Brooks L. et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients Hepatology. 23 1996 1-7
74. Jurim O. Martin P. Winston D.J. et al. Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection Liver Transpl Surg. 2 1996 370-374
75. Yoshida E.M. Wolber R.A. Mahmood W.A. Anderson F.H. Scudamore C.H. Erb S.R. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of ganciclovir Transplantation 58 1994 956-958